Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer

Journal of Clinical Oncology

Volumn 33, Issue 34, 2015, Pages 4023-4031

  Corcoran, Ryan B ^a   Atreya, Chloe E ^b   Falchook, Gerald S ^d   Kwak, Eunice L ^a   Ryan, David P ^a   Bendell, Johanna C ^d   Hamid, Omid ^c   Messersmith, Wells A ^e   Daud, Adil ^b   Kurzrock, Razelle ^f   Pierobon, Mariaelena ^g   Sun, Peng ^h   Cunningham, Elizabeth ^h   Little, Shonda ^h   Orford, Keith ^h   Motwani, Monica ^h   Bai, Yuchen ^h   Patel, Kiran ⁱ   Venook, Alan P ^b   Kopetz, Scott ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Angeles Clinic and Research Institute   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g GEORGE MASON UNIVERSITY   (United States)

^h GLAXOSMITHKLINE   (United States)

ⁱ GlaxoSmithKline ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRAMETINIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; OXIME; PTEN PROTEIN, HUMAN; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; BLURRED VISION; CANCER PATIENT; CANCER TISSUE; CHILL; CLINICAL ARTICLE; CONFERENCE PAPER; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATIGUE; FEMALE; GENE LOSS; GENE MUTATION; GENE SEQUENCE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN TISSUE; MALE; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MICROSATELLITE INSTABILITY; MOUSE; MUTATIONAL ANALYSIS; NAUSEA; NONHUMAN; OPEN STUDY; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR XENOGRAFT; VISUAL IMPAIRMENT; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOPSY; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL NEOPLASMS; FOLLOW UP; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MAP KINASE KINASE 1; MICE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OXIMES; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; PYRIDONES; PYRIMIDINONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84951745408     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.2471     Document Type: Conference Paper

References (44)

1. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
2. Tie J, Gibbs P, Lipton L, et al: Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 128:2075-2084, 2011
3. Samowitz WS, Sweeney C, Herrick J, et al: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65:6063-6069, 2005
4. Yokota T, Ura T, Shibata N, et al: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104: 856-862, 2011
5. Price TJ, Hardingham JE, Lee CK, et al: Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 29:2675-2682, 2011
6. Bokemeyer C, Van Cutsem E, Rougier P, et al: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:1466-1475, 2012
7. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl JMed 369:1023-1034, 2013
8. Morris V, Overman MJ, Jiang ZQ, et al: Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAFmutated colorectal cancer. Clin Colorectal Cancer 13:164-171, 2014
9. Tran B, Kopetz S, Tie J, et al: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:4623-4632, 2011
10. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012
11. Lochhead P, Kuchiba A, Imamura Y, et al: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105:1151-1156, 2013
12. Dienstmann R, Guinney J, Delorenzi M, et al: Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. J Clin Oncol 32:215s, 2014 (suppl 15s; abstr 3511)
13. Goldstein J, Tran B, Ensor J, et al: Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25:1032-1038, 2014
14. Bollag G, Hirth P, Tsai J, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599, 2010
15. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
16. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
17. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
18. Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901, 2012
19. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
20. Falchook GS, Lewis KD, Infante JR, et al: Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 doseescalation trial. Lancet Oncol 13:782-789, 2012
21. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAFmutated melanoma. N Engl J Med 367:107-114, 2012
22. Kopetz S, Desai J, Chan E, et al: Phase II pilot study of vermurafenib in patients metastatic, BRAFmutated colorectal cancer. J Clin Oncol 33:4032-4038, 2015
23. Infante JR, Fecher LA, Falchook GS, et al: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. Lancet Oncol 13:773-781, 2012
24. Corcoran RB, Dias-Santagata D, Bergethon K, et al: BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 3:ra84, 2010
25. Corcoran RB, Ebi H, Turke AB, et al: EGFRmediated re-Activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227-235, 2012
26. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al: Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 3:520-533, 2013
27. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-1703, 2012
28. Johnson DB, Flaherty KT, Weber JS, et al: Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAF V600-mutant melanoma experiencing progression with singleagent BRAF inhibitor. J Clin Oncol 32:3697-3704, 2014
29. McCarty KS Jr., Szabo E, Flowers JL, et al: Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46:4244s-4248s, 1986 (suppl)
30. Wulfkuhle JD, Berg D, Wolff C, et al: Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res 18:6426-6435, 2012
31. Falchook GS, Long GV, Kurzrock R, et al: Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 20:4449-4458, 2014
32. Faber AC, Corcoran RB, Ebi H, et al: BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 1:352-365, 2011
33. Corcoran RB, Rothenberg SM, Hata AN, et al: TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med 5:196ra198, 2013
34. Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977, 2010
35. Celtikci B, Carson R, Johnston PG, et al: The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF-mutant colorectal cancer cell lines. J Clin Oncol 32:236s, 2014 (suppl 15s; abstr 3594)
36. Ahronian LG, Sennott EM, Van Allen EM, et al: Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 5:358-367, 2015
37. Prahallad A, Sun C, Huang S, et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103, 2012
38. Yaeger R, Cercek A, O'Reilly EM, et al: Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 21:1313-1320, 2015
39. Tabernero J, Chan E, Baselga J, et al: VEBASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). J Clin Oncol 32:217s, 2014 (suppl 15s; abstr 3518)
40. Atreya C, Van Cutsem E, Bendell J, et al: Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol 33, 2015 (suppl 15s; abstr 103)
41. Schellens J, van Geel R, Bendell J, et al: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer. Presented at the 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, April 18-22, 2015
42. Hong D, Morris V, El Osta B, et al: Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 33, 2015 (suppl 15s; abstr 3511)
43. Mao M, Tian F, Mariadason JM, et al: Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 19:657-667, 2013
44. Kopetz S, Lemos R, Powis G: The promise of patient-derived xenografts: The best laid plans of mice and men. Clin Cancer Res 18:5160-5162, 2012